Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Shernan Holtan, MD, Todd E. DeFor, MS, Armin Rashidi, MD PhD, Alexander Khoruts, MD, Christopher Staley, PhD, Lucie M Turcotte, MD, Pamala A. Jacobson, PharmD, Daniel J. Weisdorf, MD, Margaret L. MacMillan, MD

Blood (2019) 134 (Supplement_1): 39.

https://doi.org/10.1182/blood-2019-129236

Published: 2019

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Pharmacokinetic Modeling of Fludarabine to Control Exposure and Improve Outcomes after Reduced Intensity Conditioning Transplantation

Kinjal Sanghavi, M Pharm, Anthony C. Wiseman, MD, Qing Cao, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD, Richard Brundage, PharmD PhD, John Rogosheske, PharmD, Andy Kurtzweil, PharmD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Pamala A. Jacobson, PharmD

Blood (2014) 124 (21): 3869.

https://doi.org/10.1182/blood.V124.21.3869.3869

Published: 2014

Journal Articles

Phosphoramide Mustard (PM) Population Pharmacokinetics to Estimate Inter-Individual Variability in Exposure and Identify Clinical Factors Associated with Variability in Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HCT) Patients

Kinjal Sanghavi, M Pharm, Anthony C. Wiseman, MD, Mark Kirstein, PharmD, Richard Brundage, PharmD PhD, Pamala A. Jacobson, PharmD

Blood (2014) 124 (21): 2478.

https://doi.org/10.1182/blood.V124.21.2478.2478

Published: 2014

Journal Articles

Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT)

Anthony C. Wiseman, MD, Kinjal Sanghavi, M Pharm, Qing Cao, MS, Erica D. Warlick, MD, Claudio G Brunstein, MD, John Rogosheske, PharmD, Andy Kurtzweil, PharmD, Daniel J. Weisdorf, MD, Pamala A. Jacobson, PharmD

Blood (2014) 124 (21): 1153.

https://doi.org/10.1182/blood.V124.21.1153.1153

Published: 2014

Journal Articles

Phosphoramide Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation

Anthony C. Wiseman, BS, Sanghavi Kinjal, BS, MS, Claudio Brunstein, MD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Qing Cao, MS, John Rogosheske, PharmD, Pamala A. Jacobson

Blood (2013) 122 (21): 5461.

https://doi.org/10.1182/blood.V122.21.5461.5461

Published: 2013

Journal Articles

Association Between Genetic Variants in Immune Response Genes and Outcomes After Hematopoietic Cell Transplantation

Bharat Thyagarajan, MD, PhD, Scott Jackson, MS, Saonli Basu, PhD, Pamala A. Jacobson, PharmD, Myron D Gross, PhD, Daniel J. Weisdorf, MD, Mukta Arora, MD

Blood (2011) 118 (21): 3049.

https://doi.org/10.1182/blood.V118.21.3049.3049

Published: 2011

Journal Articles

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Paul J. Martin, Barry E. Storer, Scott D. Rowley, Mary E. D. Flowers, Stephanie J. Lee, Paul A. Carpenter, John R. Wingard, Paul J. Shaughnessy, Marcel P. DeVetten, Madan Jagasia, Joseph W. Fay, Koen van Besien, Vikas Gupta, Carrie Kitko, Laura J. Johnston, Richard T. Maziarz, Mukta Arora, Pamala A. Jacobson, Daniel Weisdorf

Blood (2009) 113 (21): 5074–5082.

https://doi.org/10.1182/blood-2009-02-202937

Published: 2009

Includes: Supplemental data

Journal Articles

Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).

Pamala A. Jacobson, PharmD, Sheiren Farag El-Massah, John Rogosheske, PharmD, Amber Kerr, RN, Janel Boyle-Long, PharmD, Todd DeFor, MS, Cathryn Jennisen, PharmD, Claudio Brunstein, MD, John E. Wagner, MD, Marcie Tomblyn, MD, Daniel Weisdorf, MD

Blood (2008) 112 (11): 1116.

https://doi.org/10.1182/blood.V112.11.1116.1116

Published: 2008

Journal Articles

Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

Pamala A. Jacobson, Pharmd, Janel R Long, PharmD, John Rogosheske, PharmD, Kathleen Green, PharmD, Claudio Brunstein, MD, John E Wagner, MD, Qing Cao, MS, Jeffrey S. Miller, MD, Philip McGlave, MD, Daniel Weisdorf, MD

Blood (2008) 112 (11): 795.

https://doi.org/10.1182/blood.V112.11.795.795

Published: 2008

Journal Articles

Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT).

Pamala A. Jacobson, PharmD, Jiayin Huang, MS, Nancy Rydholm, PharmD, MyHang Tran, PharmD, Todd DeFor, MS, Jakub Tolar, MD, PhD, Paul J. Orchard, MD

Blood (2007) 110 (11): 3011.

https://doi.org/10.1182/blood.V110.11.3011.3011

Published: 2007

Journal Articles

Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

Pamala A. Jacobson, PharmD, John Rogosheske, PharmD, Kathleen Green, PharmD, Claudio Brunstein, MD, Juliet Barker, MD, Jeff Miller, MD, John Wagner, MD, Philip McGlave, MD, Ye Tan, MS, Daniel Weisdorf, MD

Blood (2005) 106 (11): 3673.

https://doi.org/10.1182/blood.V106.11.3673.3673

Published: 2005

NARROW

Pre-Transplant Serum Claudin-3 Predicts Intestinal Graft-Versus-Host Disease and Non-Relapse Mortality Risk after Allogeneic Hematopoietic Cell Transplantation

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Pharmacokinetic Modeling of Fludarabine to Control Exposure and Improve Outcomes after Reduced Intensity Conditioning Transplantation

Phosphoramide Mustard (PM) Population Pharmacokinetics to Estimate Inter-Individual Variability in Exposure and Identify Clinical Factors Associated with Variability in Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HCT) Patients

Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT)

Phosphoramide Mustard As a Biomarker Of Cyclophosphamide Exposure In Adults Receiving Reduced Intensity Conditioning Hematopoietic Cell Transplantation

Association Between Genetic Variants in Immune Response Genes and Outcomes After Hematopoietic Cell Transplantation

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).

Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT).

Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only